Skip to main content
. 2014 Apr 8;22(6):1122–1133. doi: 10.1038/mt.2014.42

Figure 5.

Figure 5

miR-26a prevents experimental pulmonary fibrosis in mice. (a) Schematic representation of protocol used to study the ability of miR-26a to prevent (subpart (A)) and to attenuate (subparts (B,C)) experimental pulmonary fibrosis. Mice were pretreated with agomiR-26a for 3 days followed by injection of bleomycin (BLM) for 28 days. miR-26a significantly alleviated (b) collagen deposition and (c) area of fibrosis induced by BLM, whereas agomiR-NC had no effects. miR-26a markedly decreased (d) hydroxyproline content and (e) mRNAs of collagenase (Col) I, Col III, matrix metalloproteinase (MMP)-2, and MMP-9 in the lungs of mice treated with BLM. (f) miR-26a inhibited BLM-induced upregulation of Col1a2, Smad4, and CTGF protein levels. Both the PCR and protein assessments are shown after normalization compared with internal controls. n = 3, *P < 0.05, **P < 0.01 versus saline; #P < 0.05 versus BLM. NC, negative control. CTGF, connective tissue growth factor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; miR, microRNA; PCR, polymerase chain reaction; TGF, transforming growth factor.